drugset
drugset / Trial / NCT05767879

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

NCT05767879 ↗

Phase 2 Unknown 28 enrolled Leiden University Medical Center Pierre Fabre Laboratories · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 2 open-label single arm intervention study administering encorafenib/binimetinib in neo-adjuvant setting followed by surgery and subsequent adjuvant encorafenib/binimetinib in in-transit melanoma patients without lymph node and distant metastases.

Timeline

Start
2022-01-01
Primary completion
2026-01-01
Completion
2026-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule 45 mg —
Subject Encorafenib Small molecule 450 mg —

Indications

cutaneous melanoma